share_log

B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42

B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42

Bof A证券将Rhythm Pharmicals的评级下调至中性,将目标股价下调至42美元
Benzinga ·  05/08 06:17

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the price target from $49 to $42.

BofA证券分析师Tazeen Ahmad将Rhythm Pharmaceuticals(纳斯达克代码:RYTM)的评级从买入降至中立,将目标价从49美元下调至42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发